Commentary
Recent studies have found the new use of antiplatelet agents for antifibrotic benefits in NAFLD, but human studies are still limited.
The authors of this meta-analysis aimed to combine the findings of existing relevant studies to investigate the effects of antiplatelet therapy in reducing or preventing advanced liver fibrosis in patients with NAFLD.
Four studies involving 2,593 patients with NAFLD were included in this meta-analysis. Preliminary evidence from this meta-analysis suggests a protective association between antiplatelet therapy and the prevalence of advanced liver fibrosis in patients with NAFLD.
